Citations

Showing 10 of 108152 citations.

Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphoma
Tang, Xinyi , Jalali, Shahrzad , Pritchett, Joshua C. , Novak, Anne J. , Yang, Zhi-Zhang , Ansell, Stephen M. , Yang, Zhi-Zhang , Pritchett, Joshua , Wu, Hongyan , Kim, Hyo Jin , Villasboas, José C.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 5, 2021 | Volume: 9 | Issue: 7 | Pages: e002662

10.1136/jitc-2021-002662 | PMID 34226281 Get It

Background CD8+ T-lymphocyte subsets defined by killer lectin-like receptor G1 (KLRG1) and CD127 expression have been reported to have an important role in infection, but their role in the setting of lymphoid malignancies, specifically follicular lymphoma (FL), has not been studied. Methods To characterize the phenotype of KLRG1/CD127-defined CD8+ subsets, surface and intracellular markers were measured by flow cytometry and Cytometry by time of flight (CyTOF), and the transcriptional profile of these cells was determined by CITE-Seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing). The functional capacity of each subset was determined, as was their impact on overall survival (OS) and event-free survival (EFS) of patients with FL. Results We found that intratumoral CD8+ cells in FL are skewed toward effector cell subsets, particularly KLRG+CD127- and KLRG1-CD127- cells over memory cell subsets, such as KLRG1-CD127+ and KLRG1+CD127+ cells. While effector subsets exhibited increased capacity to produce cytokines/granules when compared with memory subsets, their proliferative capacity and viability were found to be substantially inferior. Clinically, a skewed distribution of intratumoral CD8+ T cells favoring effector subtypes was associated with an inferior outcome in patients with FL. Increased numbers of CD127+KLRG1- and CD127+KLRG1+ were significantly associated with a favorable OS and EFS, while CD127-KLRG1- correlated with a poor EFS and OS in patients with FL. Furthermore, we demonstrated that interleukin (IL)-15 promotes CD127-KLRG1+ cell development in the presence of dendritic cells via a phosphoinositide 3-kinase (PI3K)-dependent mechanism, and treatment of CD8+ T cells with a PI3K inhibitor downregulated the transcription factors responsible for CD127-KLRG1+ differentiation. Conclusions Taken together, these results reveal not only a biological and prognostic role for KLRG1/CD127-defined CD8+ subsets in FL but also a potential role for PI3K inhibitors to manipulate the differentiation of CD8+ T cells, thereby promoting a more effective antitumor immune response.
An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries
Rollefstad, Silvia , Ikdahl, Eirik , Wibetoe, Grunde , Sexton, Joe , Crowson, Cynthia S. , Riel, Piet L. C. M. van , Graham, Ian , González‐Gay, Miguel Á. , Sfikakis, Petros P. , Tektonidou, Maria G. , Lazarini, Argyro , Vassilopoulos, Dimitrios , Kuriya, Bindee , Pascual‐Ramos, Virginia , Galarza-Delgado, D. Á. , Misra, Durga Prasanna , Borg, Andrew , Mu, Rong , Мirrakhimov, Erkin М , Gheta, Diane, Myasoedova, S. Е. , Krougly, Lev B. , Tuchyňová, Alena, Tomčík, Michal , Laštůvka, Jiří, Hořák, Pavel , Medková, Helena, Graham, Ian , Tektonidou, Maria G , Gonzalez-Gay, Miguel A , Misra, Durga Prasanna , Kitas, George D. , Rantapää‐Dahlqvist, Solbritt , Karpouzas, George , Myasoedova, Elena , Hitchon, Carol , Stoenoiu, Maria Simona , Durez, Patrick , Faggiano, Pompilio Massimo , Valentinovna Popkova, Tatiana , Vrablı́k, Michal , Semb, Anne Grete

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | July 5, 2021 | Volume: 8 | Issue: 6 | Pages: 539-548

10.1093/ehjcvp/pvab052 | PMID 34232315 Get It

Abstract Aims To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). Methods and results The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014–19. The treatment goal for BP was <140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. Conclusion We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.
Local impedance‐guided radiofrequency ablation with standard and high power: Results of a preclinical investigation
Osei, Kofi , Sulkin, Matthew S. , Hamann, Jason J., Hughes, Christopher C.W. , Shuros, Allan, Nagy, Tamás , Kapa, Suraj , Meyers, Jason D., Kapa, Suraj , Hughes, Christopher

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 5, 2021 | Volume: 32 | Issue: 8 | Pages: 2060-2068

10.1111/jce.15135 | PMID 34223691 Get It

AbstractBackgroundLocal impedance (LI) drop measured with microfidelity electrodes embedded in the tip of an ablation catheter accurately reflects tissue heating during radiofrequency (RF) ablation. Previous studies found 15–30 Ω LI drops created successful lesions, while more than 40 Ω drops were associated with steam pops. The objective of this study was to evaluate the safety and efficacy of LI‐guided ablation using standard (30 W) and high‐power (50 W) in a preclinical model.MethodsRF lesions were created in explanted swine hearts (n = 6) to assess the feasibility of LI‐guided ablation by targeting 10, 20, or 30 Ω (n = 20/group) drops. Subsequently, LI‐guided ablation was evaluated in a chronic animal model (n = 8 Canines, 25–29 kg, 30/50 W). During the index procedure point‐by‐point intercaval line ablation and left inferior pulmonary vein (PV) isolation were performed. RF duration was at the operators’ discretion but discontinued early if a 15–30 Ω drop was achieved. Operators attempted to avoid LI drops of more than 40 Ω. At 1‐month, durable conduction block was evaluated with electroanatomic mapping followed by necropsy and histopathology.ResultsIn explanted tissue, terminating ablation at 10, 20, or 30 Ω LI drops created statistically larger lesions (p < .05; 1.8 [1.6–2.4] mm, 3.3 [3.0–3.7] mm; 4.9 [4.3–5.5] mm). LI‐guided high‐power ablation in vivo significantly reduced RF duration per application compared to standard‐power (p < .05; intercaval: 8.9 ± 5.2 vs. 18.1 ± 11.0 s, PV: 9.6 ± 5.4 vs. 23.2 ± 10.3 s). LI drops of 15–40 Ω were more readily achievable for high‐power (90.1%, 318/353) than standard‐power (71.7%, 243/339). All intercaval lines and PV isolations were durable (16/16) at 1‐month. Necropsy revealed no major collateral injury to the pericardium, phrenic nerve, esophagus, or lungs. There was no pericardial effusion, stroke, tamponade, or PV stenosis. Vagal nerve injury was found in two 30 W animals after using 19.7 ± 13.9 and 19.5 ± 11.8 s RF applications.ConclusionLI‐guided ablation was found to be safe and efficacious in a chronic animal model. High‐power ablation more readily achieved more than 15 Ω drops, reduced RF duration compared with standard‐power, and had no major RF collateral injury.
Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease
Keret, Ophir , Staffaroni, Adam M. , Ringman, John M. , Goh, Sheng‐Yang M., Wolf, Amy , Allen, Isabel Elaine , Salloway, Stephen , Chhatwal, Jasmeer P. , Reyes‐Dumeyer, Dolly , Bateman, Randall J. , Morris, John C. , Joseph‐Mathurin, Nelly , Perrin, Richard J. , Gordon, Brian A. , Xiong, Chengjie , Vöglein, Jonathan , Fougère, Christian la , Martins, Ralph N. , Sohrabi, Hamid R. , Taddei, Kevin , Villemagne, Victor L. , Fulham, Michael , Masters, Colin L. , Saykin, Andrew J. , Graff‐Radford, Neill R. , Weiner, Michael W. , Cash, David M. , Chrem, Patricio, Rabinovici, Gil D. , Rosen, Howard J. , Network, Dominantly Inherited Alzheimer, Gordon, Brian A , Saykin, Andrew J , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Morris, John C , Cash, David M , Rabinovici, Gil D , Cobigo, Yann , Brickman, Adam M. , Benzinger, Tammie L.S. , Ances, Beau M. , Jucker, Mathias , Schofield, Peter R. , Brooks, William S. , Ghetti, Bernardino , Jack, Clifford R. , Allegri, Ricardo , Su, Yi , Miller, Bruce L. , Network, Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 5, 2021 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/dad2.12197 | PMID 34258377 Get It

Abstract Introduction Asymptomatic and mildly symptomatic dominantly inherited Alzheimer's disease mutation carriers (DIAD‐MC) are ideal candidates for preventative treatment trials aimed at delaying or preventing dementia onset. Brain atrophy is an early feature of DIAD‐MC and could help predict risk for dementia during trial enrollment. Methods We created a dementia risk score by entering standardized gray‐matter volumes from 231 DIAD‐MC into a logistic regression to classify participants with and without dementia. The score's predictive utility was assessed using Cox models and receiver operating curves on a separate group of 65 DIAD‐MC followed longitudinally. Results Our risk score separated asymptomatic versus demented DIAD‐MC with 96.4% (standard error = 0.02) and predicted conversion to dementia at next visit (hazard ratio = 1.32, 95% confidence interval [CI: 1.15, 1.49]) and within 2 years (area under the curve = 90.3%, 95% CI [82.3%–98.2%]) and improved prediction beyond established methods based on familial age of onset. Discussion Individualized risk scores based on brain atrophy could be useful for establishing enrollment criteria and stratifying DIAD‐MC participants for prevention trials.
Relationship Between Body Mass Index and Survival Among Critically Ill Patients With Cirrhosis
Choi, Chansong , Lennon, Ryan J , Choi, Dae Hee, Serafim, Laura Piccolo, Allen, Alina M, Kamath, Patrick S, Shah, Vijay H, Moraes, Alice Gallo de, Simonetto, Douglas A, Simonetto, Douglas A. , Choi, Chansong , De Moraes, Alice Gallo, Simonetto, Douglas A , Choi, Chansong, Lennon, Ryan J, Choi, Dae Hee, Serafim, Laura Piccolo, Allen, Alina M, Kamath, Patrick S, Shah, Vijay H, Moraes, Alice Gallo de, Simonetto, Douglas A

Mayo Clinic

Journal of Intensive Care Medicine | July 5, 2021 | Volume: 37 | Issue: 6 | Pages: 817-824

10.1177/08850666211029827 | PMID 34219539 Get It

Background: Obesity paradox is a phenomenon in which obesity increases the risk of obesity-related chronic diseases but paradoxically is associated with improved survival among obese patients with these diagnoses. Objectives: The aim of this study was to explore the obesity paradox among critically ill patients with cirrhosis admitted to the Intensive Care Unit. Methods: A retrospective cohort of 1,143 consecutive patients with cirrhosis admitted to the ICU between January of 2006 and December of 2015 was analyzed. Primary outcome of interest was in-hospital mortality with secondary end points including ICU and short-term mortality at 30 days post ICU admission. Results: Logistic regression with generalized additive models was used, controlling for clinically relevant and statistically significant factors to determine the adjusted relationship between body mass index (BMI) and ICU, post-ICU in-hospital, and 30 day mortality following ICU discharge. ICU and hospital length of stay was similar across all BMI classes. Adjusted ICU mortality was also similar when stratified by BMI. However, a significant reduction in post-ICU hospital mortality was observed in class I and II obese patients with cirrhosis (BMI 30-39.9 kg/m 2 ) compared to normal BMI (OR = 0.41; 95% CI, 0.20 to 0.83; P = 0.014). Similarly, overweight (BMI 25-29.9 kg/m 2 ) and class I and II obese patients with cirrhosis had significantly lower 30-day mortality following ICU discharge (OR = 0.52, 95% CI 0.31 to 0.87; P = 0.014; OR = 0.50, 95% CI 0.29 to 0.86; P = 0.012, respectively) compared to those with normal BMI. Conclusion: The signal of obesity paradox is suggested among critically ill patients with cirrhosis.
OTEH-6. Algorithmic approach to characterize post-treatment recurrent glioma using RNA sequencing and quantitative histopathology
Save, Akshay , Boyett, Deborah , Sisti, Michael B. , Swanson, Kristin R. , Bruce, Jeffrey N. , Canoll, Peter , Swanson, Kristin R , Argenziano, Michael , Grinband, Jack , Yoon, Hyunsoo , Li, Jing, Banu, Matei A. , McKhann, Guy M.

Mayo Clinic

Neuro-Oncology Advances | July 5, 2021 | Volume: 3 | Issue: Supplement_2 | Pages: ii11-ii11

10.1093/noajnl/vdab070.045 Get It

Abstract Introduction Distinguishing between tumor and treatment effect in post-treatment glioma, although crucial for clinical management, is difficult because contrast-enhancing regions are mixtures of recurrent tumor and reactive tissue, and definitive histopathological criteria do not exist. This study disentangles the marked intra-tumoral heterogeneity in the treatment-recurrent setting by developing an unsupervised framework to algorithmically categorize intraoperative MRI-localized biopsies into three clinically-relevant tissue clusters based on joint analysis of RNA sequencing and histopathological data. Methods A retrospective cohort of 84 MRI-localized biopsies from 37 patients with post-treatment recurrent glioblastoma underwent mRNA extraction and quantification via PLATEseq protocol. For 48 of 84 biopsies, a neighboring piece of tissue underwent quantitative histopathology based on labeling index (LI) for SOX2, CD68, NeuN, Ki67, and H&E. Correlation between LIs and gene expression for these 48 samples was performed. Genes significantly correlated (p&lt;0.05) with ≥1 marker were used for hierarchical clustering of correlation matrix, identifying three mutually-exclusive tissue-specific gene sets. These sets were then used to perform ssGSEA to categorize each of 84 biopsies into one of three tissue types. Results Correlation analysis identified 7779 genes significantly correlated with ≥1 histopathological marker. Clustering revealed three gene sets associated with specific markers: SetA-3688 genes associated with SOX2/Ki67/H&E; SetB-2418 genes associated with CD68; SetC-1673 genes associated with NeuN. ssGSEA using these sets categorized each biopsy into one of three tissue types: 27 biopsies enriched in SetA, 28 in SetB, and 29 in SetC. Conclusions Using MRI-localized biopsies with both RNAseq and histopathological data, this algorithmic approach allows development of three orthogonal tissue-specific gene sets that can be applied to characterize the heterogeneity in post-treatment recurrent glioma: SetA: genes correlated with SOX2/Ki67/H&E, representing recurrent tumor; SetB: genes correlated with CD68 (microglia) representing reactive tissue consistent with treatment effect; SetC: genes correlated with NeuN (neurons), representing infiltrated brain.
The efficiency of continuous renal replacement therapy for rewarming of patients in accidental hypothermia––An experimental study
Mendrala, Konrad , Kosiński, Sylweriusz , Podsiadło, Paweł , Pasquier, Mathieu , Mazur, Piotr , Paal, Peter , Gajniak, Dariusz, Darocha, Tomasz , Mazur, Piotr K , Podsiadło, Paweł

Mayo Clinic

Artificial Organs | July 5, 2021 | Volume: 45 | Issue: 11 | Pages: 1360-1367

10.1111/aor.14032 | PMID 34219241 Get It

AbstractSevere accidental hypothermia carries high mortality and morbidity and is often treated with invasive extracorporeal methods. Continuous veno‐venous hemodiafiltration (CVVHDF) is widely available in intensive care units. We sought to provide theoretical basis for CVVHDF use in rewarming of hypothermic patients. CVVHDF system was used in the laboratory setting. Heat balance and transferred heat units were evaluated for the system without using blood. We used 5L of crystalloid solution at the temperature of approximately 25°C, placed in a thermally insulated tank (representing the “central compartment” of a hypothermic patient). Time of warming the central compartment from 24.9 to 30.0°C was assessed with different flow combinations: “blood” (central compartment fluid) 50 or 100 or 150 mL/min, dialysate solution 100 or 1500 mL/h, and substitution fluid 0 or 500 mL/h. The total circulation time was 1535 minutes. There were no differences between heat gain values on the filter depending on blood flow (P = .53) or dialysate flow (P = .2). The mean heating time for “blood” flow rates 50, 100, and 150 mL/min was 113.7 minutes (95% CI, 104.9‐122.6 minutes), 83.3 minutes (95% CI, 76.2‐90.3 minutes), and 74.7 minutes (95% CI, 62.6‐86.9 minutes), respectively (P < .01). The respective median rewarming rate for different “blood” flows was 3.6°C/h (IQR, 3.0‐4.2°C/h), 4.8 (IQR, 4.2‐5.4°C/h), and 5.4 (IQR, 4.8‐6.0°C/h), respectively (P < .01). The dialysate flow did not affect the warming rate. Based on our experimental model, CVVHDF may be used for extracorporeal rewarming, with the rewarming rates increasing achieved with higher blood flow rates.
Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
Suryawanshi, Yogesh R. , Schulze, Autumn J.

Mayo Clinic

Viruses | July 4, 2021 | Volume: 13 | Issue: 7 | Pages: 1294

10.3390/v13071294 | PMID 34372501 Get It

Glioblastoma is one of the most difficult tumor types to treat with conventional therapy options like tumor debulking and chemo- and radiotherapy. Immunotherapeutic agents like oncolytic viruses, immune checkpoint inhibitors, and chimeric antigen receptor T cells have revolutionized cancer therapy, but their success in glioblastoma remains limited and further optimization of immunotherapies is needed. Several oncolytic viruses have demonstrated the ability to infect tumors and trigger anti-tumor immune responses in malignant glioma patients. Leading the pack, oncolytic herpesvirus, first in its class, awaits an approval for treating malignant glioma from MHLW, the federal authority of Japan. Nevertheless, some major hurdles like the blood–brain barrier, the immunosuppressive tumor microenvironment, and tumor heterogeneity can engender suboptimal efficacy in malignant glioma. In this review, we discuss the current status of malignant glioma therapies with a focus on oncolytic viruses in clinical trials. Furthermore, we discuss the obstacles faced by oncolytic viruses in malignant glioma patients and strategies that are being used to overcome these limitations to (1) optimize delivery of oncolytic viruses beyond the blood–brain barrier; (2) trigger inflammatory immune responses in and around tumors; and (3) use multimodal therapies in combination to tackle tumor heterogeneity, with an end goal of optimizing the therapeutic outcome of oncolytic virotherapy.
Response to the Letter to the Editor From Jialal and Sood: “New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency After ACTH Stimulation Using Specific Cortisol Assays”
Javorsky, Bradley R. , Raff, Hershel , Carroll, Ty B , Colón-Franco, Jessica M , Findling, James W. , Jit Singh, Ravinder, Carroll, Ty B , Algeciras‐Schimnich, Alicia , Singh, Ravinder

Mayo Clinic

Journal of the Endocrine Society | July 4, 2021 | Volume: 5 | Issue: 9 | Pages: No page available

10.1210/jendso/bvab113 | PMID 34278181 Get It

A core outcome set for the treatment of pregnant women with pregestational diabetes: an international consensus study
Kgosidialwa, Oratile , Bogdanet, Delia , Egan, Aoife M. , O’Shea, Paula , Newman, Christine , Griffin, Tomás P. , McDonagh, C, O'Shea, C, Carmody, Louise , Cooray, Shamil D. , Anastasiou, E., Wender‐Ożegowska, Ewa, Clarson, Cheril , Spadola, Alexandra, Alvarado, Fernanda , Noctor, Eoin , Dempsey, Eugene , Napoli, Angela , Galjaard, Sander , Loeken, Mary R. , Maresh, M., Gillespie, Paddy , Valk, Harold de, Biesty, Linda , Devane, Declan , Dunne, Fidelma , Kgosidialwa, O , Bogdanet, D , Egan, A M , Cooray, S D , O'Shea, Paula M , Gillespie, Paddy , Dunne, Fidelma P , Crowther, Caroline Anne , Agostini, Andrea , Newman, Christine

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | July 4, 2021 | Volume: 128 | Issue: 11 | Pages: 1855-1868

10.1111/1471-0528.16825 | PMID 34218508 Get It

Objective To develop a core outcome set (COS) for randomised controlled trials (RCTs) evaluating the effectiveness of interventions for the treatment of pregnant women with pregestational diabetes mellitus (PGDM). Design A consensus developmental study. Setting International. Population Two hundred and five stakeholders completed the first round. Methods The study consisted of three components. (1) A systematic review of the literature to produce a list of outcomes reported in RCTs assessing the effectiveness of interventions for the treatment of pregnant women with PGDM. (2) A three‐round, online eDelphi survey to prioritise these outcomes by international stakeholders (including healthcare professionals, researchers and women with PGDM). (3) A consensus meeting where stakeholders from each group decided on the final COS. Main outcome measures All outcomes were extracted from the literature. Results We extracted 131 unique outcomes from 67 records meeting the full inclusion criteria. Of the 205 stakeholders who completed the first round, 174/205 (85%) and 165/174 (95%) completed rounds 2 and 3, respectively. Participants at the subsequent consensus meeting chose 19 outcomes for inclusion into the COS: trimester‐specific haemoglobin A1c, maternal weight gain during pregnancy, severe maternal hypoglycaemia, diabetic ketoacidosis, miscarriage, pregnancy‐induced hypertension, pre‐eclampsia, maternal death, birthweight, large for gestational age, small for gestational age, gestational age at birth, preterm birth, mode of birth, shoulder dystocia, neonatal hypoglycaemia, congenital malformations, stillbirth and neonatal death. Conclusions This COS will enable better comparison between RCTs to produce robust evidence synthesis, improve trial reporting and optimise research efficiency in studies assessing treatment of pregnant women with PGDM. Tweetable abstract 165 key stakeholders have developed #Treatment #CoreOutcomes in pregnant women with #diabetes existing before pregnancy.